Cardica Completes Enrollment For PAS-Port(R) System Clinical Trial For Use In Bypass Surgery

Cardica, Inc.
(Nasdaq: CRDC) today announced it completed enrollment of approximately 220
patients in a pivotal clinical trial to evaluate the safety and efficacy of
its PAS-Port(R) Proximal Anastomosis System during coronary artery bypass
graft (CABG) surgery. The PAS-Port system, which is commercially available
in Japan and Europe, creates a secure connection, or anastomosis, between a
vein graft and the aorta, the main artery in the human body, during bypass
procedures.

“The PAS-Port system’s automated reliability and precise engineering
facilitate rapid, consistent anastomoses during both on and off-pump bypass
surgeries,” said John Puskas, M.D., Chief of Cardiac Surgery, Emory
Crawford Long Hospital, Associate Chief of Cardiothoracic Surgery, Emory
University, and principal investigator of the trial. “By eliminating the
need to clamp the aorta, this device may reduce the risk of neurological
complications and mortality associated with beating heart bypass procedures
and may ultimately play a key role in advancing less invasive cardiac
surgery.”

The pivotal, prospective, randomized trial is being conducted in the
United States under an Investigational Device Exemption. Approximately 220
patients have been enrolled at 14 sites in the United States and Europe.
Two venous bypass grafts were randomly selected in each patient to be
connected to the aorta using either the PAS-Port device or the conventional
hand-sewn technique. Patients will receive a follow-up angiogram nine
months after their procedure to determine patency (or degree of openness of
the vein graft) of both PAS-Port and control grafts. If the results of this
trial are favorable, the company plans to submit a 510(k) application for
the PAS-Port system to the U.S. Food and Drug Administration in early 2008.

“The completion of enrollment in this pivotal trial signifies a major
step forward both for Cardica and for the field of minimally invasive
cardiac surgery,” said Bernard A. Hausen, M.D., Ph.D., president and chief
executive officer of Cardica, Inc.

The innovative design of the PAS-Port system allows the surgeon to load
the bypass graft and rapidly complete the anastomosis, typically in
approximately two minutes, with little or no injury to the bypass graft
vessel or the aorta. As of December 31, 2006, over 4,800 PAS-Port systems
had been sold in Japan and Europe, and today this product is used in more
than 20 percent of all proximal anastomoses performed using a vein bypass
graft during CABG surgeries in Japan.

In previous clinical trials conducted in Europe, the 6 month patency
rate with anastomoses completed with the PAS-Port system ranged from
approximately 87 to 98 percent compared to an average of 84 percent
reported in the literature for traditional hand-sewn anastomoses at the
same time point.

About CABG Surgery

Coronary heart disease causes one out of every five deaths in the
United States, making it the single largest killer of Americans. While
other treatment alternatives exist, studies show that CABG surgery achieves
the best long-term patient outcome for coronary heart disease as measured
by survival rate and need for re-intervention. In 2007, an estimated
220,000 to 250,000 CABG procedures will be performed in the United States,
each requiring approximately five anastomoses, often considered the most
critical step of the surgery. The current method of performing an
anastomosis in a CABG procedure utilizes technically demanding, tedious and
time-consuming hand sewn sutures to connect a bypass graft vessel to the
aorta and to small diameter coronary vessels. Clamping of the aorta when
creating a conventional hand-sewn anastomosis has been associated with
neurological complications.

About Cardica, Inc.

Cardica designs and manufactures automated anastomosis systems for
coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures
with easy-to-use automated systems, Cardica provides cardiovascular
surgeons with rapid, reliable and consistently reproducible anastomoses, or
connections of blood vessels, often considered the most critical aspect of
the CABG procedure.

Cardica’s C-Port(R) Distal Anastomosis Systems are marketed in Europe
and the United States. The PAS-Port(R) Proximal Anastomosis System is
marketed in Europe and Japan and is being evaluated in a pivotal trial in
the United States and Europe. Cardica also is developing additional devices
to facilitate vascular and other surgical procedures. Go to
cardica for more information.

Forward Looking Statements

This press release contains “forward-looking” statements, including
statements relating to the ongoing clinical trial, efficacy and potential
application for U.S. regulatory approval of the PAS-Port Proximal
Anastomosis System and other matters. Any statements contained in this
press release that are not historical facts may be deemed to be
forward-looking statements. The words “believe,” “plan,” “expect,”
“estimate,” “intend” and “will” or similar expressions are intended to
identify forward-looking statements. There are a number of important
factors that could cause Cardica’s results to differ materially from those
indicated by these forward-looking statements, including risks associated
with the timing and success of clinical trial using the PAS- Port Proximal
Anastomosis System, as well as other risks detailed from time to time in
Cardica’s SEC reports, including its Quarterly Report on Form 10-Q for the
quarter ended December 31, 2006. Cardica does not undertake any obligation
to update forward-looking statements. You are encouraged to read the
Company’s reports filed with the U.S. Securities and Exchange Commission,
available at sec.

Cardica, Inc.
cardica/

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.